{"preliminary_commentary":{"by_channel":{"x_thread":4,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["pembrolizumab/vibostolimab"]],"indication":"unresectable stage III non-small cell lung cancer","name":"KEYVIBE-006","nct_id":"NCT05298423","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=keyvibe-006-nct05298423. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"KEYVIBE-006","arms":[{"description":"For the first 3 cycles, participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) intravenously (IV) on Day 1 plus 3 cycles of investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy during Cycles 2, 3. Participants receive pembrolizumab/vibostolimab for Cycles 4-20 or until discontinuation (up to \\~14 months). Cycles 1-20 are 21-day cycles.\n\nAs of protocol amendment 4, participants receiving pembrolizumab/vibostolimab must stop ongoing treatment with pembrolizumab/vibostolimab and will be offered the option to transition to post-cCRT durvalumab consolidation therapy, to complete up to 1 year of consolidation immunotherapy.","label":"pembrolizumab/vibostolimab coformulation+chemotherapy+radiotherapy","type":"EXPERIMENTAL"},{"description":"For the first 3 cycles, participants will receive investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy during Cycles 2 and 3. Following concurrent chemoradiotherapy (cCRT), participants receive durvalumab 10 mg/kg every 2 weeks for up to an additional 26 cycles or until discontinuation (up to approximately 14 months). cCRT Cycles 1-3=21-day cycles; durvalumab Cycles 1-26=14-day cycles.","label":"chemotherapy+radiotherapy+durvalumab","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-06-15","type":"ACTUAL"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":{"count":610,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"pembrolizumab/vibostolimab","otherNames":["MK-7684A"],"type":"BIOLOGICAL"},{"name":"durvalumab","otherNames":["IMFINZI®"],"type":"BIOLOGICAL"},{"name":"cisplatin","otherNames":["PLATINOL-AQ®"],"type":"DRUG"},{"name":"pemetrexed","otherNames":["ALIMTA®"],"type":"DRUG"},{"name":"etoposide","otherNames":["TOPOSAR®"],"type":"DRUG"},{"name":"carboplatin","otherNames":["PARAPLATIN®"],"type":"DRUG"},{"name":"paclitaxel","otherNames":["TAXOL®"],"type":"DRUG"},{"name":"thoracic radiotherapy","otherNames":[],"type":"RADIATION"}],"last_update":"2026-08-28","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab With Pembrolizumab) in Combination With Concurrent Chemoradiotherapy Followed by MK-7684A Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III NSCLC","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2026-06-15","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants Who Experience at Least One Adverse Event (AE)","timeFrame":"Up to approximately 48 months"},{"measure":"Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)","timeFrame":"Up to approximately 48 months"}],"references":[],"start_date":{"date":"2022-05-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)","url":"https://clinicaltrials.gov/study/NCT05298423"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/keyvibe-006-nct05298423"}